Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
Information source: Innovative Medical
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma
Intervention: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Innovative Medical Official(s) and/or principal investigator(s):
Robert Noecker, MD, Principal Investigator, Affiliation: UPMC Eye Center
Summary
Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as
adjunctive therapy
Clinical Details
Official title: Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- · Male or female > 18 years of age
- Diagnosis of open-angle glaucoma or ocular hypertension
- IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
- Presently on latanoprost monotherapy for at least 6 weeks
- Ability to provide informed consent and likely to complete all study visits
Exclusion Criteria:
- · Known contraindication or allergy to brimonidine or any of its components
- Subjects must be naive to brimonidine 0. 2% or brimonidine Purite 0. 15% and
dorzolamide 2%
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension (e. g. uveitis,
ocular infections, or severe dry eye). Patients with chronic mild blepharitis,
cataract, age-related macular degeneration, or background diabetic retinopathy
may be enrolled at the discretion of the investigator.
- Required use of ocular medications other than the study medications during the
study (intermittent use of artificial tear product is allowed).
- Corneal abnormalities
- History of intraocular surgery within the last 3 months
- Female patients of childbearing potential who are pregnant, lactating, planning
a pregnancy, or not using a reliable form of birth control
- Visual field loss, which in the opinion of the investigator, is functionally
significant, or evidence of progressive visual field loss within the last year.
Locations and Contacts
Dr. Noecker, Pittsburgh, Pennsylvania 15213, United States
Additional Information
Last updated: May 30, 2007
|
